PedAM
Pediatric Disease Annotations & Medicines
| Disease | astrocytoma |
| Phenotype | |tuberous sclerosis |
| Sentences | 61 |
| PubMedID- 25227171 | Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
| PubMedID- 24276039 | Background: brain subependymal giant cell astrocytomas (segas) in patients with tuberous sclerosis have been reported to respond to everolimus. |
| PubMedID- 20643042 | [subependymal giant cell astrocytoma in tuberous sclerosis complex. |
| PubMedID- PMC3518234 | Down-regulation of mtor kinase by everolimus has been successfully used for the therapy of subependymal giant-cell astrocytomas in patients with tuberous sclerosis. |
| PubMedID- 22408430 | Likewise, everolimus was approved by fda for the treatment of progressive endocrine tumours of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease and for patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (ts) (http://www.fda.gov). |
| PubMedID- 24757527 | Everolimus is effective in the treatment of large angiomiolypomas (aml) in patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc). |
| PubMedID- 23325902 | Objective: to report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 23612453 | Everolimus is an oral mtor inhibitor currently approved in various countries for treatment-refractory advanced renal cell carcinoma; progressive, unresectable, advanced pancreatic neuroendocrine tumours; and renal angiomyolipoma and subependymal giant-cell astrocytomas associated with tuberous sclerosis complex. |
| PubMedID- 24244540 | Everolimus has been approved for second-line therapy of patients with renal cell carcinoma after failure of treatment with sunitinib and for the treatment of papillary renal carcinoma, pancreatic neuroendocrine tumor, some types of breast cancer, and subependymal giant cell astrocytoma associated with tuberous sclerosis [24]–[28]. |
| PubMedID- 23582392 | Everolimus for astrocytomas in tuberous sclerosis. |
| PubMedID- 23183057 | The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. |
Page: 1 2